
News|Articles|October 8, 2012
FDA gives green light to ANDA for chewable diabetes tablet
FDA has approved Boston Therapeutic’s petition to file an Abbreviated New Drug Application (ANDA) for a new, chewable tablet formulation of the diabetes drug metformin hydrochloride. The company plans to market the new formulation under the name Pazamet.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Overlooked bladder nerves now thought to reduce UTI burden through pain signaling, study shows
2
Real-World Usage of Biologics in Psoriatic Arthritis
3
FDA approves $2.7 million gene therapy for rare metabolic disorder
4
Medicare beneficiaries are paying more for price-negotiated drugs, survey finds
5





















